Daiichi Sankyo Co.’s edoxaban, the latest in a new group of blood thinners aimed at replacing warfarin, was found to be as effective as the drug that has been the standard of care for 60 years, in a study.
Drugmakers from GlaxoSmithKline Plc to Lupin Ltd. are grappling with Indian distributors, whose demand for maintaining commissions threatens to erode profits after the South Asian nation imposed price controls.
ICICI Securities Ltd., the investment-banking arm of India’s biggest private lender, formed a partnership with Japan’s GCA Savvian Group Corp. to advise on cross-border mergers between the two countries.
Daiichi Sankyo Co.’s experimental blood thinner edoxaban was as effective and less risky than standard treatment warfarin in a study that may position the Japanese company to compete with drugmakers including Pfizer Inc., Johnson & Johnson and Bristol-Myers Squibb Co.
Asian stocks fell, with the benchmark regional index declining from a four-month high, as the U.S. Federal Reserve begins a two-day policy meeting at which it’s forecast to reduce the pace of bond buying.